The startup describes its software as providing clinical labs with more streamlined and accurate analysis, interpretation and reporting for accelerating personalized medicine programs.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The contract, to provide comprehensive genomic sequencing to VA cancer patients, affords significant opportunities to conduct clinical research, a company executive said.
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
The $8 per share deal will allow Illumina to tap into the long-read sequencing market, while also heading off competition from other firms, analyst writes.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Prostate cancer survivor Bryce Olson says genomic sequencing shows the way forward in cancer treatment, rather than the one-size-fits-all approach.
The partnership will also enable Foundation Medicine to move into ex-US markets like Japan, where it is working with drugmaker Chugai.
The study, conducted with St. Jude Children's Research Hospital, showed a 78 percent predictive sensitivity two days before the onset of infection.
In a first, the agency approved Adaptive Biotechnologies' clonoSEQ assay to detect MRD in acute lymphoblastic leukemia and multiple myeloma, a measure that can predict risk of relapse.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Chief Commercial Officer Tom Civik said he sees reimbursement of its NGS test as opening the door for liquid biopsy reimbursement as well.
In January 2016, Independence Blue Cross and NantHealth announced the nation's first coverage for a whole genome sequencing and proteome molecular diagnostic platform, but it's mostly slipped under the radar since then. What's going on?
Lower costs for capital and sequencing, a friendlier regulatory and reimbursement environment and growth in precision medicine are among driving factors.
MedCity CONVERGE speaker discusses the challenges facing reimbursement and how ECRI Institute simplifies it.
Experts went into the nitty-gritty aspects of how the community oncology setting can implement precision medicine trials.